Cytokinetics(CYTK)
Focus: Cytokinetics is a public biotechnology company focused on small-molecule therapeutics for cardiovascular, neurology, oncology, rare disease, and respiratory indications. The company has one launched product (MYQORZO/aficamten) and a robust pipeline spanning heart failure, hypertrophic cardiomyopathy, and ALS.
Profile data last refreshed 5h ago · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Open Jobs
76+59 this month
Hot — 78 jobs added in 30d
Net +59 (78 new, 19 removed). Aggressive expansion phase.
Should You Work at Cytokinetics?
AI assessmentAttractive for early-career scientists/clinicians seeking rare-disease impact and launch-stage experience, but high execution risk and cash constraints make this suitable only for risk-tolerant candidates.
Why Work Here
- Early-stage commercial launch with MYQORZO creating immediate market exposure and commercial hiring surge (11 open Commercial roles).
Data completeness
7/9 — Strong
Company HealthStrong
Pipeline
Late-stage
11 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$8M
Key Products
Launch15.8yr
First-in-class cardiac myosin inhibitor recently approved; early commercial traction in rare HCM market with long exclusivity runway.
Help build intelligence for Cytokinetics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.